Clinical Research Directory
Browse clinical research sites, groups, and studies.
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Sponsor: Ebima Clifford Okundaye
Summary
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.
Official title: Use of NAD Oxidase Modulation Agent QRX3 for Prevention and Treatment of Progressive Chronic Kidney Disease
Key Details
Gender
All
Age Range
18 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
3000
Start Date
2025-10
Completion Date
2027-07
Last Updated
2025-09-08
Healthy Volunteers
No
Interventions
QRX-3
capsule
Locations (1)
Neukidney Inc
Pasedena, Texas, United States